In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health, Beauty And Wellness News: NPA On NIS, AHPA JAMA Letter, Zero Recall Two

This article is powered by The Rose Sheet

Executive Summary

NPA wants to work with FDA to develop broader, more transparent medical food definition; FTC FY 2018 report notes enforcements against supplement firms making false claims of memory and cognitive benefits; Zero Xtreme recalled for second time in two years after found containing sibutramine; and more news.

Advertisement

Related Content

FDA Regulatory Oversight No Impediment To Drug-Spiked Supplements, Study Finds
Ohio's Proposed Ban On Sales Marks Kratom Industry's Latest Battlefront
Health, Beauty And Wellness News: Nestle Compleat, FDA Nutrition Strategy
UAS Labs Expands Probioitic Portfolio: Health And Wellness Industry News
Ad Firm Behind Bogus Weight Loss Claims Fined $2M: Health And Wellness Industry News
FDA Health & Wellness Product Recalls For July 6 & 13, 2016

Topics

Advertisement
UsernamePublicRestriction

Register

RS122386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel